KR102439717B1 - C5 다형성을 갖는 환자에서 보체 매개 질병의 치료에 사용하기 위한 오르니토도로스 모우바타 보체 억제제 - Google Patents

C5 다형성을 갖는 환자에서 보체 매개 질병의 치료에 사용하기 위한 오르니토도로스 모우바타 보체 억제제 Download PDF

Info

Publication number
KR102439717B1
KR102439717B1 KR1020167036998A KR20167036998A KR102439717B1 KR 102439717 B1 KR102439717 B1 KR 102439717B1 KR 1020167036998 A KR1020167036998 A KR 1020167036998A KR 20167036998 A KR20167036998 A KR 20167036998A KR 102439717 B1 KR102439717 B1 KR 102439717B1
Authority
KR
South Korea
Prior art keywords
complement
agent
subject
polymorphism
complement pathway
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167036998A
Other languages
English (en)
Korean (ko)
Other versions
KR20170016893A (ko
Inventor
윈 에이치 웨스턴-데이비스
Original Assignee
볼루션 이뮤노 파마슈티컬스 에스에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 볼루션 이뮤노 파마슈티컬스 에스에이 filed Critical 볼루션 이뮤노 파마슈티컬스 에스에이
Publication of KR20170016893A publication Critical patent/KR20170016893A/ko
Application granted granted Critical
Publication of KR102439717B1 publication Critical patent/KR102439717B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020167036998A 2014-06-06 2015-06-08 C5 다형성을 갖는 환자에서 보체 매개 질병의 치료에 사용하기 위한 오르니토도로스 모우바타 보체 억제제 Active KR102439717B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1410116.6 2014-06-06
GBGB1410116.6A GB201410116D0 (en) 2014-06-06 2014-06-06 Method of treatment
PCT/EP2015/062742 WO2015185760A1 (en) 2014-06-06 2015-06-08 Ornithodoros moubata complement inhibitor for use in the treatment of complement-mediated diseases in patients with c5 polymorphism

Publications (2)

Publication Number Publication Date
KR20170016893A KR20170016893A (ko) 2017-02-14
KR102439717B1 true KR102439717B1 (ko) 2022-09-02

Family

ID=51266841

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167036998A Active KR102439717B1 (ko) 2014-06-06 2015-06-08 C5 다형성을 갖는 환자에서 보체 매개 질병의 치료에 사용하기 위한 오르니토도로스 모우바타 보체 억제제

Country Status (16)

Country Link
US (3) US11052129B2 (enExample)
EP (1) EP3151851B1 (enExample)
JP (2) JP7045133B2 (enExample)
KR (1) KR102439717B1 (enExample)
CN (1) CN106659767B (enExample)
AU (1) AU2015270396B2 (enExample)
BR (1) BR112016028446A2 (enExample)
CA (1) CA2951175A1 (enExample)
DK (2) DK3151851T3 (enExample)
ES (2) ES2906630T3 (enExample)
GB (1) GB201410116D0 (enExample)
IL (1) IL249237B (enExample)
MX (1) MX382757B (enExample)
PL (2) PL3151851T3 (enExample)
RU (1) RU2700932C2 (enExample)
WO (1) WO2015185760A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
WO2016198133A1 (en) * 2015-06-08 2016-12-15 Volution Immuno Pharmaceuticals Sa Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
GB201602802D0 (en) * 2016-02-17 2016-03-30 Volution Immuno Pharmaceuticals Sa Method of treatment
JP2019521105A (ja) * 2016-06-07 2019-07-25 ノバルティス アーゲー 補体ｃ５多型を有する患者を治療するための抗ｃ５抗体
SE540754C2 (en) * 2016-11-30 2018-10-30 Ikea Supply Ag Molding of fiber blanks into three-dimensional fiber block
JP7153669B2 (ja) * 2017-04-21 2022-10-14 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 瘢痕性眼炎症障害の治療のためのコバーシン
DK3612208T5 (da) 2017-04-21 2024-09-02 Volution Immuno Pharmaceuticals Sa Coversin til behandlingen af autoimmune sygdomme med blisterdannelse
WO2019186084A1 (en) * 2018-03-26 2019-10-03 The University Of Liverpool Anti-complement histones
WO2020053206A1 (en) * 2018-09-10 2020-03-19 Volution Immuno Pharmaceuticals Sa Coversin for use in the treatment of rheumatic diseases
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008029167A1 (en) * 2006-09-08 2008-03-13 Varleigh Limited Method of treating peripheral nerve disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054033A9 (en) * 1995-08-30 2005-03-10 Human Genome Sciences, Inc. Methods and compositions for treating and preventing infection using human interferon regulatory factor 3
GB0312619D0 (en) * 2003-06-02 2003-07-09 Evolutec Ltd Complement inhibitors
ATE427356T1 (de) 2003-06-02 2009-04-15 Varleigh Ltd Komplementinhibitoren aus zecken
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
PL2061501T3 (pl) * 2006-09-08 2016-01-29 Volution Immuno Pharmaceuticals Sa Sposób leczenia zaburzeń oddechowych
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
GB0906779D0 (en) * 2009-04-20 2009-06-03 Natural Environment Res Council Composition
JP5840623B2 (ja) 2010-01-08 2016-01-06 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 気道のウイルス感染症の治療に用いるｅｖ５７６
TW201418707A (zh) * 2012-09-21 2014-05-16 Alexion Pharma Inc 補體組分ｃ５拮抗劑之篩選分析
GB201410116D0 (en) 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
DK3612208T5 (da) 2017-04-21 2024-09-02 Volution Immuno Pharmaceuticals Sa Coversin til behandlingen af autoimmune sygdomme med blisterdannelse

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008029167A1 (en) * 2006-09-08 2008-03-13 Varleigh Limited Method of treating peripheral nerve disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Nishimura, Jun-ichi, et al. "Genetic variants in C5 and poor response to eculizumab." New England Journal of Medicine 370.7 (2014): 632-639.*

Also Published As

Publication number Publication date
PL3151851T3 (pl) 2022-04-04
ES2906630T3 (es) 2022-04-19
US20180193417A1 (en) 2018-07-12
DK3151851T3 (da) 2022-02-28
CA2951175A1 (en) 2015-12-10
NZ727053A (en) 2023-10-27
RU2700932C2 (ru) 2019-09-24
IL249237B (en) 2020-09-30
RU2016151179A3 (enExample) 2019-01-22
GB201410116D0 (en) 2014-07-23
MX2016016139A (es) 2017-07-28
RU2016151179A (ru) 2018-07-16
MX382757B (es) 2025-03-13
IL249237A0 (en) 2017-02-28
KR20170016893A (ko) 2017-02-14
DK3302519T3 (da) 2022-02-28
EP3151851B1 (en) 2021-12-01
AU2015270396B2 (en) 2020-07-16
WO2015185760A1 (en) 2015-12-10
US20210283221A1 (en) 2021-09-16
EP3151851A1 (en) 2017-04-12
JP6767396B2 (ja) 2020-10-14
CN106659767B (zh) 2022-08-30
JP2018516944A (ja) 2018-06-28
JP2017518316A (ja) 2017-07-06
BR112016028446A2 (pt) 2017-10-24
CN106659767A (zh) 2017-05-10
US20170196936A1 (en) 2017-07-13
AU2015270396A1 (en) 2016-12-15
PL3302519T3 (pl) 2022-04-25
JP7045133B2 (ja) 2022-03-31
US11052129B2 (en) 2021-07-06
ES2906632T3 (es) 2022-04-19

Similar Documents

Publication Publication Date Title
KR102439717B1 (ko) C5 다형성을 갖는 환자에서 보체 매개 질병의 치료에 사용하기 위한 오르니토도로스 모우바타 보체 억제제
KR100603683B1 (ko) 활막세포 단백질
JP6339415B2 (ja) ニューレグリンの下流タンパク質であるニューキナーゼ
US20240009270A1 (en) Coversin for the treatment of autoimmune blistering diseases
EP3302519B1 (en) Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
EP2804618B1 (en) Method of treating diabetes using non-glycosylated apolipoprotein a-iv
JP2008092950A (ja) 低及び中間コンダクタンスのカルシウム活性化されたカリウムチャネル及びその使用
US20040167066A1 (en) Cleavage and polyadenylation complex of precursor mrna
JP2008522162A (ja) Ｍｅｒの診断用および治療用の作用薬
KR20100080769A (ko) 과민성 반응의 조절자
US7972813B2 (en) Tetrodotoxin-resistant sodium channel alpha subunit
EP1853628B1 (en) Sodium channel protein type iiii alpha-subunit splice variant
US20120094935A1 (en) Methods for creating or identifying compounds that bind tumor necrosis factor alpha
KR20190126801A (ko) 전신 홍반성 루푸스를 치료하기 위한 가용성 cd24의 사용 방법
NZ727053B2 (en) Ornithodoros moubata complement inhibitor for use in the treatment of complement-mediated diseases in patients with c5 polymorphism
US20080200408A1 (en) Deletion mutants of tetrodotoxin-resistant sodium channel alpha subunit
WO2003018776A9 (en) IDENTIFICATION OF THE IκBNS PROTEIN AND ITS PRODUCTS
BRPI0609209A2 (pt) uso de mgc4504

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20161229

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200527

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220428

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220817

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220830

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220831

End annual number: 3

Start annual number: 1

PG1601 Publication of registration